Evidence map›Paper›PMID 42204626›Full record

ReviewJournal of medical case reports2026

Dual valve Achromobacter endocarditis in a long-term acute care unit: a case report and review of the literature.

Mohamed Abdelgalil

Abstract readCase ReportsReview
In one paragraph

Review in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mohamed AbdelgalilNational Ribat University, Khartoum, Sudan. ameorphan@gmail.com.ORCID http://orcid.org/0000-0001-5476-3845

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAchromobacter xylosoxidans is an opportunistic, gram-negative organism that primarily affects immunocompromised individuals or those with indwelling medical devices. Although generally considered of low virulence, it has been increasingly recognized as a cause of serious infections, including infective endocarditis (IE), which is associated with significant morbidity and mortality and often poses therapeutic challenges. CASE PRESENTATION: We present the case of a 69-year-old Middle Eastern woman with a complex medical history significant for coronary artery bypass grafting, end-stage renal disease requiring hemodialysis via a tunneled catheter, chronic respiratory failure secondary to tracheomalacia, atrial fibrillation, and persistent vegetative state following a prior cardiac arrest. The patient was transferred from the intensive care unit to a long-term acute care facility and subsequently developed recurrent polymicrobial bacteremia. Blood cultures repeatedly isolated Achromobacter xylosoxidans despite targeted antimicrobial therapy. Transthoracic echocardiography revealed a small mobile vegetation on the posterior mitral valve leaflet associated with mild-to-moderate mitral regurgitation. A follow-up study approximately 1 month later demonstrated new aortic valve involvement, consistent with disease progression. Despite antimicrobial therapy guided by susceptibility testing and catheter exchange, persistent bacteremia continued. Surgical intervention was deemed not feasible due to the patient's extreme frailty and high operative risk. During her clinical course, she developed ventilator-associated pneumonia secondary to multidrug-resistant Klebsiella pneumoniae, progressed to septic shock with lactic acidosis, and ultimately suffered a bradycardic arrest. DISCUSSION: Achromobacter xylosoxidans endocarditis is a rare condition that predominantly affects immunocompromised individuals or those with intravascular devices. Effective management is challenging due to the organism's intrinsic and acquired antimicrobial resistance, the frequent persistence of bacteremia, and the potential requirement for surgical intervention. In patients for whom surgery is not a viable option, outcomes can be poor despite prolonged, targeted antimicrobial therapy.

conclusionThis case underscores the challenges of managing native valve infective endocarditis caused by Achromobacter xylosoxidans in medically fragile patients. The disease may progress despite appropriate antimicrobial therapy, particularly when surgical intervention is not feasible. Therefore, multidisciplinary evaluation and individualized management are essential in such high-risk cases.

Indexed as

Achromobacter denitrificansAortic ValveBacteremiaEndocarditis, BacterialGram-Negative Bacterial InfectionsMitral ValveMitral Valve InsufficiencyAgedAnti-Bacterial AgentsEchocardiographyFemaleHumansAnti-Bacterial AgentsAntibioticEchocardiographyInfective endocarditisSepsisValve

Identifiers

PMID42204626
PMCPMC13221767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.